MediWound Ltd. (NASDAQ:MDWD) Receives $33.50 Consensus PT from Analysts

MediWound Ltd. (NASDAQ:MDWD) has earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $33.50.

Several equities research analysts have commented on the company. Wall Street Zen upgraded MediWound from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. HC Wainwright reissued a “buy” rating and set a $36.00 target price (up previously from $31.00) on shares of MediWound in a research report on Friday, November 21st. Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research report on Thursday.

Institutional Investors Weigh In On MediWound

Several institutional investors and hedge funds have recently modified their holdings of the stock. Meitav Investment House Ltd. lifted its position in shares of MediWound by 825.7% during the third quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after purchasing an additional 260,116 shares in the last quarter. Millennium Management LLC increased its stake in MediWound by 355.6% during the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock worth $3,160,000 after buying an additional 136,884 shares during the period. Bank of America Corp DE lifted its holdings in MediWound by 157.3% in the 3rd quarter. Bank of America Corp DE now owns 11,864 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 7,253 shares in the last quarter. UBS Group AG boosted its position in MediWound by 15.3% in the 3rd quarter. UBS Group AG now owns 76,301 shares of the biopharmaceutical company’s stock valued at $1,375,000 after buying an additional 10,102 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of MediWound by 90.4% during the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 723 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Stock Performance

MediWound stock opened at $17.70 on Friday. MediWound has a 1 year low of $14.14 and a 1 year high of $22.50. The firm has a 50 day moving average price of $18.12 and a 200 day moving average price of $18.24. The company has a market cap of $227.27 million, a price-to-earnings ratio of -9.32 and a beta of 0.07.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.57. The company had revenue of $5.43 million for the quarter, compared to analyst estimates of $6.56 million. MediWound had a negative net margin of 98.43% and a negative return on equity of 62.11%. Sell-side analysts predict that MediWound will post -2.66 EPS for the current year.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.